Get the latest news, insights, and market updates on OPK (OPKO Health, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
OPKO Health (OPK): Losses Accelerate 25% Annually, Revenue Forecast Trails Market Ahead of Earnings
OPKO Health (OPK) remains unprofitable, posting accelerating losses at a rate of 25% per year over the past five years. While revenue is forecast to grow at 4.1% per year, which is well behind the broader US market's 10.3% rate, investors may remain cautious as the company continues to miss profitability milestones and recent margin improvement appears elusive. See our full analysis for OPKO Health. Next, we will line up these headline numbers against the most widely followed market... Oct 31, 2025 - $OPK
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest. […] Oct 31, 2025 - $OPK
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered wa Oct 30, 2025 - $OPK
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Re Oct 29, 2025 - $OPK
OPKO Health: Q3 Earnings Snapshot
MIAMI (AP) — Opko Health Inc. OPK) on Wednesday reported third-quarter profit of $21.6 million. On a per-share basis, the Miami-based company said it had net income of 3 cents. Oct 29, 2025 - $OPK
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of +250.00% and -3.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Oct 29, 2025 - $OPK
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of m Oct 29, 2025 - $OPK
Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Oct 29, 2025 - $OPK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple